After AdComm rejection, Mallinckrodt’s stannsoporfin gets stiff-armed at FDA.

The FDA has issued a complete response letter to Mallinckrodt’s jaundice drug stannsoporfin. Mallinckrodt plans to talk to the FDA in the coming months before deciding the fate of a drug it acquired in an $80 million buyout last year. [ABSTRACT FROM AUTHOR]